Molecular Mechanism of Curcumin and Its Analogs as Multifunctional Compounds against Pancreatic Cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–87. doi:10.1016/j.ejca.2018.07.005
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Goess R, Friess H. A look at the progress of treating pancreatic cancer over the past 20 years. Expert Rev Anticancer Ther. 2018;18(3):295–304. doi:10.1080/14737140.2018.1428093
   PubMed Web of Science ®Google Scholar
• Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. JCO. 1997;15(6):2403–13. doi:10.1200/JCO.1997.15.6.2403
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O’Reilly DA, Cunningham D, Wadsley J, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24. doi:10.1016/S0140-6736(16)32409-6
   PubMed Web of Science ®Google Scholar
• Gupta SC, Sung B, Kim JH, Prasad S, Li S, Aggarwal BB. Multitargeting by turmeric, the golden spice: from kitchen to clinic. Mol Nutr Food Res. 2013;57(9):1510–28. doi:10.1002/mnfr.201100741
   PubMed Web of Science ®Google Scholar
• Zhao W, Zhou X, Qi G, Guo Y. Curcumin suppressed the prostate cancer by inhibiting JNK pathways via epigenetic regulation. J Biochem Mol Toxicol. 2018;32(5):e22049–5. doi:10.1002/jbt.22049
   PubMed Web of Science ®Google Scholar
• Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: a review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer. 2011;10:12–9. doi:10.1186/1476-4598-10-12
   PubMed Web of Science ®Google Scholar
• Ye MX, Li Y, Yin H, Zhang J. Curcumin: updated molecular mechanisms and intervention targets in human lung cancer. Int J Mol Sci. 2012;13(3):3959–78. doi:10.3390/ijms13033959
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xue Y-b, Li H, Qiu D, Wang Z-w, Tan S-s. Inhibition of Cell Survival by Curcumin Is Associated with Downregulation of Cell Division Cycle 20 (Cdc20) in Pancreatic Cancer Cells. Nutrients. 2017;9(2):109–15. doi:10.3390/nu9020109
   PubMed Web of Science ®Google Scholar
• Zhou H, Beevers CS, Huang S. The targets of curcumin. Curr Drug Targets. 2011;12(3):332–47. doi:10.2174/138945011794815356
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Najafi M, Makvandi P, Zarrabi A, Farkhondeh T, Samarghandian S. Versatile role of curcumin and its derivatives in lung cancer therapy. J Cell Physiol. 2020;235(12):9241–68. doi:10.1002/jcp.29819
   PubMed Web of Science ®Google Scholar
• Wang Y, Yu J, Cui R, Lin J, Ding X. Curcumin in treating breast cancer: a review. J Lab Autom. 2016;21(6):723–31. doi:10.1177/2211068216655524
   PubMedGoogle Scholar
• Song X, Zhang M, Dai E, Luo Y. Molecular targets of curcumin in breast cancer (Review). Mol Med Rep. 2019;19(1):23–9. doi:10.3892/mmr.2018.9665
   PubMed Web of Science ®Google Scholar
• Darvesh AS, Aggarwal BB, Bishayee A. Curcumin and liver cancer: a review. Curr Pharm Biotechnol. 2012;13(1):218–28. doi:10.2174/138920112798868791
   PubMed Web of Science ®Google Scholar
• Jalili-Nik M, Soltani A, Moussavi S, Ghayour-Mobarhan M, Ferns GA, Hassanian SM, Avan A. Current status and future prospective of Curcumin as a potential therapeutic agent in the treatment of colorectal cancer. J Cell Physiol. 2018;233(9):6337–45. doi:10.1002/jcp.26368
   PubMed Web of Science ®Google Scholar
• Afsane B, Ferns F. Effect of curcumin and its derivates on gastric cancer: molecular mechanisms. Nutr Cancer. 2021;73(9):1553–69. doi:10.1080/01635581.2020.1808232
   PubMed Web of Science ®Google Scholar
• Teymouri M, Pirro M, Johnston TP, Sahebkar A. Curcumin as a multifaceted compound against human papilloma virus infection and cervical cancers: a review of chemistry, cellular, molecular, and preclinical features. Biofactors. 2017;43(3):331–46. doi:10.1002/biof.1344
   PubMed Web of Science ®Google Scholar
• Terlikowska KM, Witkowska AM, Zujko ME, Dobrzycka B, Terlikowski SJ. Potential application of curcumin and its analogues in the treatment strategy of patients with primary epithelial ovarian cancer. Int J Mol Sci. 2014;15(12):21703–22. doi:10.3390/ijms151221703
   PubMed Web of Science ®Google Scholar
• Jordan BC, Mock CD, Thilagavathi R, Selvam C. Molecular mechanisms of curcumin and its semisynthetic analogues in prostate cancer prevention and treatment. Life Sci. 2016;152:135–44. doi:10.1016/j.lfs.2016.03.036
   PubMed Web of Science ®Google Scholar
• Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, Williamsson C, Sasor A, Borg D, Bauden M, Andersson R. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol. 2016;12(16):1929–46. doi:10.2217/fon-2016-0010
   PubMed Web of Science ®Google Scholar
• Ercan G, Karlitepe A, Ozpolat B. Pancreatic cancer stem cells and therapeutic approaches. Anticancer Res. 2017;37(6):2761–75. doi:10.21873/anticanres.11628
   PubMed Web of Science ®Google Scholar
• Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, Shemi A, Golan T, Domb AJ, Yavin E, et al. Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110(51):20723–8. doi:10.1073/pnas.1314307110
   PubMed Web of Science ®Google Scholar
• Xiaodong S, Xinge L. Curcumin induces apoptosis of pancreatic cancer cells by inhibiting Ras-ERK and Shh-GLI1 signal pathways. Chinese J Pathophy. 2012;28:996–1000. doi:10.3969/j.issn.1000-4718.201206.007
   Google Scholar
• César P-MC, Ernesto S-R, Elena A-O, Elizabeth O-S, Verónica A-V. Curcumin stabilizes p53 by interaction with NAD(P)H:quinone oxidoreductase 1 in tumor-derived cell lines. Redox Biol. 2020;28:101320. doi:10.1016/j.redox.2019.101320
   PubMed Web of Science ®Google Scholar
• Malhotra L, Goyal HKV, Jhuria S, Dev K, Kumar S, Kumar M, Kaur P, Ethayathulla AS. Curcumin rescue p53Y220C in BxPC-3 pancreatic adenocarcinomas cell line: evidence-based on computational, biophysical, and in vivo studies. Biochim Biophys Acta Gen Subj. 2021;1865(2):129807. doi:10.1016/j.bbagen.2020.129807
   PubMed Web of Science ®Google Scholar
• Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta. 2010;1799(10-12):775–87. doi:10.1016/j.bbagrm.2010.05.004
   PubMed Web of Science ®Google Scholar
• Amit S, Ben-Neriah Y. NF-kappaB activation in cancer: a challenge for ubiquitination- and proteasome-based therapeutic approach. Semin Cancer Biol. 2003;13(1):15–28. doi:10.1016/S1044-579X(02)00096-2
   PubMed Web of Science ®Google Scholar
• Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer. 2004;101(10):2351–62. doi:10.1002/cncr.20605
   PubMed Web of Science ®Google Scholar
• Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res. 2007;67(8):3853–61. doi:10.1158/0008-5472.CAN-06-4257
   PubMed Web of Science ®Google Scholar
• Basha R, Connelly SF, Sankpal UT, Nagaraju GP, Patel H, Vishwanatha JK, Shelake S, Tabor-Simecka L, Shoji M, Simecka JW, et al. Small molecule tolfenamic acid and dietary spice curcumin treatment enhances antiproliferative effect in pancreatic cancer cells via suppressing Sp1, disrupting NF-kB translocation to nucleus and cell cycle phase distribution. J Nutr Biochem. 2016;31:77–87. doi:10.1016/j.jnutbio.2016.01.003
   PubMed Web of Science ®Google Scholar
• Suske G. The Sp-family of transcription factors. Gene. 1999;238(2):291–300. doi:10.1016/S0378-1119(99)00357-1
   PubMed Web of Science ®Google Scholar
• Sankpal UT, Maliakal P, Bose D, Kayaleh O, Buchholz D, Basha R. Expression of specificity protein transcription factors in pancreatic cancer and their association in prognosis and therapy. Curr Med Chem. 2012;19(22):3779–86. doi:10.2174/092986712801661077
   PubMed Web of Science ®Google Scholar
• Guan H, Cai J, Zhang N, Wu J, Yuan J, Li J, Li M. Sp1 is upregulated in human glioma, promotes MMP-2-mediated cell invasion and predicts poor clinical outcome. Int J Cancer. 2012;130(3):593–601. doi:10.1002/ijc.26049
   PubMed Web of Science ®Google Scholar
• Jutooru I, Chadalapaka G, Lei P, Safe S. Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J Biol Chem. 2010;285(33):25332–44. doi:10.1074/jbc.M109.095240
   PubMed Web of Science ®Google Scholar
• Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29(6 Suppl 16):15–8. doi:10.1053/sonc.2002.37263
   PubMed Web of Science ®Google Scholar
• Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, Sho M, Nakajima Y, Kanehiro H, Hisanaga M, et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer. 1999;79(9-10):1553–63. doi:10.1038/sj.bjc.6690248
   PubMed Web of Science ®Google Scholar
• Nagaraju GP, Zhu S, Ko JE, Ashritha N, Kandimalla R, Snyder JP, Shoji M, El-Rayes BF. Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer. Cancer Lett. 2015;357(2):557–65. doi:10.1016/j.canlet.2014.12.007
   PubMed Web of Science ®Google Scholar
• Bimonte S, Barbieri A, Palma G, Luciano A, Rea D, Arra C. Curcumin inhibits tumor growth and angiogenesis in an orthotopic mouse model of human pancreatic cancer. Biomed Res Int. 2013;2013:1–8. doi:10.1155/2013/810423
   Web of Science ®Google Scholar
• Song X, Liu Z, Yu Z. EGFR Promotes the Development of Triple Negative Breast Cancer Through JAK/STAT3 Signaling. Cancer Manag Res. 2020;12:703–17. doi:10.2147/CMAR.S225376
   PubMed Web of Science ®Google Scholar
• Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J. H. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 1984;309(5967):418–25. doi:10.1038/309418a0
   PubMed Web of Science ®Google Scholar
• Huh YH, Kim SH, Kim SJ, Chun JS. Differentiation status-dependent regulation of cyclooxygenase-2 expression and prostaglandin E2 production by epidermal growth factor via mitogen-activated protein kinase in articular chondrocytes. J Biol Chem. 2003;278(11):9691–7. doi:10.1074/jbc.M211360200
   PubMed Web of Science ®Google Scholar
• Lev-Ari S, Starr A, Vexler A, Karaush V, Loew V, Greif J, Fenig E, Aderka D, Ben-Yosef R. Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity. Anticancer Res. 2006;26(6B):4423–30.
   PubMed Web of Science ®Google Scholar
• Ishiko T, Sakamoto K, Yamashita S, Masuda Y, Kamohara H, Mita S, Hirashima M, Ogawa M. Carcinoma-cells express IL-8 and the IL-8 receptor - their inhibition attenuates the growth of carcinoma-cells. Int J Oncol. 1995;6(1):119–22. doi:10.3109/02656739509004953
   PubMed Web of Science ®Google Scholar
• Hidaka H, Ishiko T, Furuhashi T, Kamohara H, Suzuki S, Miyazaki M, Ikeda O, Mita S, Setoguchi T, Ogawa M. Curcumin inhibits interleukin 8 production and enhances interleukin 8 receptor expression on the cell surface:impact on human pancreatic carcinoma cell growth by autocrine regulation. Cancer. 2002;95(6):1206–14. doi:10.1002/cncr.10812
   PubMed Web of Science ®Google Scholar
• Farh KK-H, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, Burge CB, Bartel DP. The widespread impact of mammalian microRNAs on mRNA repression and evolution. Science. 2005;310(5755):1817–21. doi:10.1126/science.1121158
   PubMed Web of Science ®Google Scholar
• Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350–5. doi:10.1038/nature02871
   PubMed Web of Science ®Google Scholar
• Liu J, Gao J, Du Y, Li Z, Ren Y, Gu J, Wang X, Gong Y, Wang W, Kong X. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer. 2012;131(3):683–91. doi:10.1002/ijc.26422
   PubMed Web of Science ®Google Scholar
• Yang D, Li Y, Zhao D. Curcumin induces apoptotic cell death in human pancreatic cancer cells via the miR-340/XIAP signaling pathway. Oncol Lett. 2017;14(2):1811–6. doi:10.3892/ol.2017.6321
   PubMed Web of Science ®Google Scholar
• Ma J, Fang B, Zeng F, Pang H, Zhang J, Shi Y, Wu X, Cheng L, Ma C, Xia J, et al. Curcumin inhibits cell growth and invasion through up-regulation of miR-7 in pancreatic cancer cells. Toxicol Lett. 2014;231(1):82–91. doi:10.1016/j.toxlet.2014.09.014
   PubMed Web of Science ®Google Scholar
• Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther. 2008;7(3):464–73. doi:10.1158/1535-7163.MCT-07-2272
   PubMed Web of Science ®Google Scholar
• Korać P, Antica M, Matulić M. MiR-7 in Cancer Development. Biomedicines. 2021;9(3):325–2. doi:10.3390/biomedicines9030325
   PubMed Web of Science ®Google Scholar
• Wang Q, Qu C, Xie F, Chen L, Liu L, Liang X, Wu X, Wang P, Meng Z. Curcumin suppresses epithelial-to-mesenchymal transition and metastasis of pancreatic cancer cells by inhibiting cancer-associated fibroblasts. Am J Cancer Res. 2017;7(1):125–33.
   PubMed Web of Science ®Google Scholar
• Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol. 2007;18(5):460–6. doi:10.1016/j.copbio.2007.10.007
   PubMed Web of Science ®Google Scholar
• Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–11. doi:10.1038/35102167
   PubMed Web of Science ®Google Scholar
• Ning X, Du Y, Ben Q, Huang L, He X, Gong Y, Gao J, Wu H, Man X, Jin J, et al. Bulk pancreatic cancer cells can convert into cancer stem cells(CSCs) in vitro and 2 compounds can target these CSCs. Cell Cycle. 2016;15(3):403–12. doi:10.1080/15384101.2015.1127471
   PubMed Web of Science ®Google Scholar
• Li W, Wang Z, Xiao X, Han L, Wu Z, Ma Q, Cao L. Curcumin attenuates hyperglycemia-driven EGF-induced invasive and migratory abilities of pancreatic cancer via suppression of the ERK and AKT pathways. Oncol Rep. 2019;41(1):650–8. doi:10.3892/or.2018.6833
   PubMed Web of Science ®Google Scholar
• Sun XD, Liu XE, Huang DS. Curcumin reverses the epithelial-mesenchymal transition of pancreatic cancer cells by inhibiting the Hedgehog signaling pathway. Oncol Rep. 2013;29(6):2401–7. doi:10.3892/or.2013.2385
   PubMed Web of Science ®Google Scholar
• Cao L, Xiao X, Lei J, Duan W, Ma Q, Li W. Curcumin inhibits hypoxia-induced epithelial‑mesenchymal transition in pancreatic cancer cells via suppression of the hedgehog signaling pathway. Oncol Rep. 2016;35(6):3728–34. doi:10.3892/or.2016.4709
   PubMed Web of Science ®Google Scholar
• Zhao Z, Li C, Xi H, Gao Y, Xu D. Curcumin induces apoptosis in pancreatic cancer cells through the induction of forkhead box O1 and inhibition of the PI3K/Akt pathway. Mol Med Rep. 2015;12(4):5415–22. doi:10.3892/mmr.2015.4060
   PubMed Web of Science ®Google Scholar
• Mengyuan P, Feng Q, Dan H, Xia Q, Yuan Z. Reversal effects of curcumin on gemcitabine-resistant pancreatic cancer SW1990 cells and its mechanism study. China Pharmacy. 2019;30:1192–7. doi:10.6039/j.issn.1001-0408.2019.09.09
   Google Scholar
• Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 2001;15(17):2177–96. doi:10.1101/gad.914401
   PubMed Web of Science ®Google Scholar
• Sahu RP, Batra S, Srivastava SK. Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. Br J Cancer. 2009;100(9):1425–33. doi:10.1038/sj.bjc.6605039
   PubMed Web of Science ®Google Scholar
• Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781–810. doi:10.1146/annurev.cellbio.20.010403.113126
   PubMed Web of Science ®Google Scholar
• Clevers H, Nusse R. Wnt/β-catenin signaling and ­disease. Cell. 2012;149(6):1192–205. doi:10.1016/j.cell.2012.05.012
   PubMed Web of Science ®Google Scholar
• Li L, Su Y, Ren X. Curcumin regulates the growth of pancreatic cancer cell lines SW1990 by inhibiting Wnt/β-catenin signaling. J Shangqiu Normal Univ. 2014;30:81–5.
   Google Scholar
• Padhye S, Banerjee S, Chavan D, Pandye S, Swamy KV, Ali S, Li J, Dou QP, Sarkar FH. Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm Res. 2009;26(11):2438–45. doi:10.1007/s11095-009-9955-6
   PubMed Web of Science ®Google Scholar
• Padhye S, Yang H, Jamadar A, Cui QC, Chavan D, Dominiak K, McKinney J, Banerjee S, Dou QP, Sarkar FH. New difluoro Knoevenagel condensates of curcumin, their Schiff bases and copper complexes as proteasome inhibitors and apoptosis inducers in cancer cells. Pharm Res. 2009;26(8):1874–80. doi:10.1007/s11095-009-9900-8
   PubMed Web of Science ®Google Scholar
• Azmi AS, Ali S, Banerjee S, Bao B, Maitah MN, Padhye S, Philip PA, Mohammad RM, Sarkar FH. Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent apoptotic mechanism. Am J Transl Res. 2011;3(4):374–82. doi:10.1016/B978-0-12-385524-4.00004-0
   PubMed Web of Science ®Google Scholar
• Bao B, Ali S, Banerjee S, Wang Z, Logna F, Azmi AS, Kong D, Ahmad A, Li Y, Padhye S, et al. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res. 2012;72(1):335–45. doi:10.1158/0008-5472.CAN-11-2182
   PubMed Web of Science ®Google Scholar
• Sun T, Yang M, Chen S, Balk S, Pomerantz M, Hsieh C-L, Brown M, Lee G-SM, Kantoff PW. The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer. Prostate. 2012;72(10):1093–103. doi:10.1002/pros.22456
   PubMed Web of Science ®Google Scholar
• Sun T, Wang X, He HH, Sweeney CJ, Liu SX, Brown M, Balk S, Lee G-S, Kantoff PW. MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene. 2014;33(21):2790–800. doi:10.1038/onc.2013.230
   PubMed Web of Science ®Google Scholar
• Sarkar S, Dubaybo H, Ali S, Goncalves P, Kollepara SL, Sethi S, Philip PA, Li Y. Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA. Am J Cancer Res. 2013;3(5):465–77. doi:10.1016/S1098-3015(10)70951-7
   PubMed Web of Science ®Google Scholar
• Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5):283–96. doi:10.1038/nrm3330
   PubMed Web of Science ®Google Scholar
• Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008;8(4):253–67. doi:10.1099/0022-1317-77-8-1935
   PubMed Web of Science ®Google Scholar
• Borriello A, Caldarelli I, Bencivenga D, Criscuolo M, Cucciolla V, Tramontano A, Oliva A, Perrotta S, Della Ragione F. p57(Kip2) and cancer: time for a critical appraisal. Mol Cancer Res. 2011;9(10):1269–84. doi:10.1158/1541-7786.MCR-11-0220
   PubMed Web of Science ®Google Scholar
• Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene. 2008;27(S1):S71–S83. doi:10.1038/onc.2009.45
   PubMed Web of Science ®Google Scholar
• Bao B, Ali S, Ahmad A, Azmi AS, Li Y, Banerjee S, Kong D, Sethi S, Aboukameel A, Padhye SB, et al. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS One. 2012;7(12):e50165. 12. doi:10.1371/journal.pone.0050165
   PubMed Web of Science ®Google Scholar
• Sato A, Kudo C, Yamakoshi H, Uehara Y, Ohori H, Ishioka C, Iwabuchi Y, Shibata H. Curcumin analog GO-Y030 is a novel inhibitor of IKKβ that suppresses NF-κB signaling and induces apoptosis . Cancer Sci. 2011;102(5):1045–51. doi:10.1111/j.1349-7006.2011.01886.x
   PubMed Web of Science ®Google Scholar
• Hutzen B, Friedman L, Sobo M, Lin L, Cen L, De Angelis S, Yamakoshi H, Shibata H, Iwabuchi Y, Lin J. Curcumin analogue GO-Y030 inhibits STAT3 activity and cell growth in breast and pancreatic carcinomas. Int J Oncol. 2009;35(4):867–72. doi:10.3892/ijo_00000401
   PubMed Web of Science ®Google Scholar
• Majumder K, Skube S, Salzwedel AO, Arora N, Giri B, Modi S, Garg B, Banerjee S, Saluja A, Dudeja V. Curcumin Derivative FLLL-31 Sensitizes Pancreatic Cancer Cells to TRAIL Induced Cell Death Through Death Receptor Up-Regulation. Gastroenterology. 2016;150(4):S1200. doi:10.1016/S0016-5085(16)34058-6
   Web of Science ®Google Scholar
• Friedman L, Lin L, Ball S, Bekaii-Saab T, Fuchs J, Li P-K, Li C, Lin J. Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells. Anticancer Drugs. 2009;20(6):444–9. doi:10.1097/CAD.0b013e32832afc04
   PubMed Web of Science ®Google Scholar
• Kasinski AL, Du Y, Thomas SL, Zhao J, Sun S-Y, Khuri FR, Wang C-Y, Shoji M, Sun A, Snyder JP, et al. Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol. 2008;74(3):654–61. doi:10.1124/mol.108.046201
   PubMed Web of Science ®Google Scholar
• Nagaraju GP, Zhu S, Wen J, Farris AB, Adsay VN, Diaz R, Snyder JP, Mamoru S, El-Rayes BF. Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer. Cancer Lett. 2013;341(2):195–203. doi:10.1016/j.canlet.2013.08.002
   PubMed Web of Science ®Google Scholar
• Wu P, Wang X, Ma Y, Xu X, Liu W, Sheng Z, Chen M, Zhou R, Zhang K, Goodin S, et al. (3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells. Bioorg Chem. 2020;101:104022–9. doi:10.1016/j.bioorg.2020.104022
   PubMed Web of Science ®Google Scholar
• Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today. 2012;17(1-2):71–80. doi:10.1016/j.drudis.2011.09.009
   PubMed Web of Science ®Google Scholar
• Bisht S, Mizuma M, Feldmann G, Ottenhof NA, Hong S-M, Pramanik D, Chenna V, Karikari C, Sharma R, Goggins MG, et al. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol Cancer Ther. 2010;9(8):2255–64. doi:10.1158/1535-7163.MCT-10-0172
   PubMed Web of Science ®Google Scholar
• Ranjan AP, Mukerjee A, Helson L, Gupta R, Vishwanatha JK. Efficacy of liposomal curcumin in a human pancreatic tumor xenograft model: inhibition of tumor growth and angiogenesis. Anticancer Res. 2013;33:3603–9. doi:10.1007/s11839-013-0432-4
   PubMed Web of Science ®Google Scholar
• Mahmud M, Piwoni A, Filiczak N, Janicka M, Gubernator J. Long-circulating curcumin-loaded liposome formulations with high incorporation efficiency, stability and anticancer activity towards pancreatic adenocarcinoma cell lines in vitro. PLoS ONE. 2016;11(12):e0167787–23. doi:10.1371/journal.pone.0167787
   PubMed Web of Science ®Google Scholar
• Yallapu MM, Ebeling MC, Khan S, Sundram V, Chauhan N, Gupta BK, Puumala SE, Jaggi M, Chauhan SC. Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment. Mol Cancer Ther. 2013;12(8):1471–80. doi:10.1158/1535-7163.MCT-12-1227
   PubMed Web of Science ®Google Scholar
• Seeta Rama Raju G, Pavitra E, Nagaraju GP, Ramesh K, El-Rayes BF, Yu JS. Imaging and curcumin delivery in pancreatic cancer cell lines using PEGylated α-Gd2(MoO4)3 mesoporous particles . Dalton Trans. 2014;43(8):3330–8. doi:10.1039/c3dt52692e
   PubMed Web of Science ®Google Scholar
• Cheng T, Zhang Z, Shen H, Jian Z, Li J, Chen Y, Shen Y, Dai X. Topically applicated curcumin/gelatin-blended nanofibrous mat inhibits pancreatic adenocarcinoma by increasing ROS production and endoplasmic reticulum stress mediated apoptosis. J Nanobiotechnol. 2020;18(1):1–12. doi:10.1186/s12951-020-00687-2
   PubMed Web of Science ®Google Scholar
• Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14(14):4491–9. doi:10.1158/1078-0432.CCR-08-0024
   PubMed Web of Science ®Google Scholar
• Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, Nishimura T, Mori Y, Masui T, Kawaguchi Y, et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol. 2011;68(1):157–64. doi:10.1007/s00280-010-1470-2
   PubMed Web of Science ®Google Scholar
• Pastorelli D, Fabricio AS, Giovanis P, D’Ippolito S, Fiduccia P, Soldà C, Buda A, Sperti C, Bardini R, Da Dalt G, et al. Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: results of a prospective phase II trial. Pharmacol Res. 2018;132:72–9. doi:10.1016/j.phrs.2018.03.013
   PubMed Web of Science ®Google Scholar